Debio 0932

DRUG2 trials

Sponsors

Debiopharm International SA

Conditions

CancerLymphomaNeoplasmsNon-small Cell Lung CancerSolid Tumors

Phase 1

Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma

CompletedNCT01168752

Debiopharm International SACancer, Lymphoma, Neoplasms +1

Start: 2010-04-30End: 2013-04-30Updated: 2014-02-03

A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]

TerminatedNCT01714037

Debiopharm International SANon-small Cell Lung Cancer

Start: 2012-08-31End: 2014-11-30Updated: 2015-04-08

Related Papers

Debio0932, a second-generation oral heat shock protein (HSP) inhibitor, in patients with advanced cancer-results of a first-in-man dose-escalation study with a fixed-dose extension phase.

2015-02-0225 citations

Final results from the phase I study expansion cohort of Debio0932, an oral HSP90 inhibitor, in patients with solid tumors.

Journal of Clinical Oncology2014-05-20

The HALO study: A phase I-II of the oral HSP90 inhibitor Debio0932 in combination with SOC in first- and second-line therapy of advanced NSCLC.

Journal of Clinical Oncology2014-05-20